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Abstract 
Cancer is a common cause of death worldwide. Despite significant advances in cancer treatments, the morbidity and 
mortality are still enormous. Tumor heterogeneity, especially intratumoral heterogeneity, is a significant reason under-
lying difficulties in tumor treatment and failure of a number of current therapeutic modalities, even of molecularly 
targeted therapies. The development of a virtually noninvasive “liquid biopsy” from the blood has been attempted to 
characterize tumor heterogeneity. This review focuses on cell-free circulating tumor DNA (ctDNA) in the bloodstream 
as a versatile biomarker. ctDNA analysis is an evolving field with many new methods being developed and optimized 
to be able to successfully extract and analyze ctDNA, which has vast clinical applications. ctDNA has the potential to 
accurately genotype the tumor and identify personalized genetic and epigenetic alterations of the entire tumor. In 
addition, ctDNA has the potential to accurately monitor tumor burden and treatment response, while also being able 
to monitor minimal residual disease, reducing the need for harmful adjuvant chemotherapy and allowing more rapid 
detection of relapse. There are still many challenges that need to be overcome prior to this biomarker getting wide 
adoption in the clinical world, including optimization, standardization, and large multicenter trials.
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Background
Cancers figure among the leading causes of morbidity 
and mortality worldwide, with approximately 14 mil-
lion new cases and 8.2 million cancer-related deaths in 
2012 [1]. The number of new cases is expected to rise by 
approximately 70%, from 14 million in 2012 to 22 mil-
lion within the next two decades [1]. Surgery, adjuvant 
systemic treatment, and targeted therapies have mark-
edly improved cancer outcomes over the past 10 years. 
However, many patients still die due to tumor metas-
tasis and drug resistance [2]. Tumor heterogeneity and 
clonal evolution introduce significant challenges in 
designing effective treatment strategies [3, 4]. Different 
tumor cells show distinct morphologic and phenotypic 
features, including cellular morphology, gene expres-
sion, metabolism, motility, proliferation, and metastatic 
potential [5]. Heterogeneity occurs both between tumors 
(intertumoral heterogeneity) and within tumors (intra-
tumoral heterogeneity). Intratumoral heterogeneity, 
with spatially separated heterogeneous somatic muta-
tions and chromosomal imbalances in primary tumors 
or metastases, provides a tremendous challenge for can-
cer treatment, since examining a tissue biopsy of a por-
tion of tumor mass could miss therapeutically relevant 
lesions [6]. In addition, clonal evolution in the primary 
tumor is partly fueled by intratumoral heterogeneity. 
When metastases develop, clonal evolution continues 
to occur under the selection pressure of anti-cancer 
treatments [6–8]. Molecularly targeted cancer therapies 
require serial monitoring of the tumor genomic makeup. 
However, obtaining consecutive tissue biopsies is costly, 
sometimes inaccessible, and associated with potential 
morbidity. Therefore, inability to capture spatial and 
temporal heterogeneity during tumor evolution results 
in the failure of cancer systemic treatments, requiring 
the development of novel approaches to detect tumor 
heterogeneity.
Recent progress in the analysis of blood samples for cir-
culating tumor cells (CTC) or cell-free circulating tumor 
DNA (ctDNA) provides rapid, cost-effective, and nonin-
vasive “liquid biopsy” surrogates, which give important 
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complementary information on therapeutic targets and 
drug resistance mechanisms in cancer patients [9, 10]. 
Apoptotic or necrotic tumor cells discharge DNA frag-
ments into the circulating blood system. These DNA 
fragments are called cell-free ctDNA. Cell-free DNA 
was initially reported by Mandel and Metais [11] in 1948 
in the blood of healthy individuals. Elevated levels of 
ctDNA have been found in blood plasma and serum of 
cancer patients compared to healthy controls [12–21]. 
This review focuses on ctDNA and discusses the biologi-
cal and technical aspects, clinical applications in cancer 
diagnostics, and perspectives and challenges.
Circulating tumor cells (CTC)
CTCs are tumor cells shed into the bloodstream from 
primary and metastatic tumor deposits [22]. CTCs were 
initially detected in 1869 by an Australian physician 
Thomas Ashworth in a breast cancer patient’s blood [23]. 
Analysis of CTCs in peripheral blood of cancer patients 
holds great promise for the early detection of invasive 
cancer and the management of advanced disease. CTC 
detection and retrieval require elaborate methods and 
cumbersome processes, including highly sensitive and 
specific analytic methods and complex enrichment steps 
[24, 25]. Although techniques of CTC isolation are stead-
ily improved with increasingly sophisticated technologies 
developed over the past years [26, 27], CTC identification 
and characterization still remain technically challenging. 
CTCs occur at very low concentrations of one tumor cell 
in the background of millions of blood cells. Particularly, 
patients with early-stage cancer present with extremely 
low CTC concentration, thus needing more sensitive 
assays and/or analysis of larger blood volumes, which is 
usually not feasible [25]. Furthermore, mechanism(s) 
causing CTCs to break off from the tumor are elusive; 
thus it is unclear whether CTCs represent the entire 
makeup of cancer cells in the tumor or only a subpopula-
tion. CTCs and ctDNA likely have complementary roles 
as cancer biomarker since separate approaches possess 
distinct advantages. CTCs visualize intact cells for mor-
phologic identification, associate with the metastatic pro-
cess, and provide the unique opportunity for functional 
study and more comprehensive information including 
DNA, RNA, and protein-based molecular profiling [28]. 
Compared with CTCs, ctDNA is easier to isolate and 
more sensitive to detect. Therefore, as an alternative to 
CTC analysis, ctDNA appears to potentially provide supe-
rior source of genetic information, with the development 
of next-generation sequencing technologies.
Origin and biological characteristics of ctDNA
Cell-free DNA is released into circulation by vari-
ous pathologic and normal physiologic mechanisms. 
Fragments of DNA are shed into the bloodstream from 
dying cells during cellular turnover or apoptotic and 
necrotic cells [29, 30]. Under normal physiologic circum-
stances, apoptotic and necrotic cells are cleared by infil-
trating phagocytes and cell-free DNA levels are relatively 
low. However, this mechanism does not act effectively 
in the tumor mass. Most cell-free DNA fragments are 
measured between 180 and 200 base pairs (bp) [30–32], 
suggesting apoptosis as the predominant source of cell-
free DNA in the circulation [30, 33, 34]. In solid tumors, 
cell-free DNA can be also released through necrosis, 
autophagy, and other physiologic events induced by 
microenvironmental stress and treatment pressure [21, 
35]. Unlike apoptosis, necrosis generates larger DNA 
fragments due to an incomplete and random digestion 
of genomic DNA [36]. Nevertheless, not all cell-free 
DNA originates from cell death. Live cells spontaneously 
release newly synthesized DNA as part of a homeostati-
cally regulated system [29, 37–39]. Stimulation of lym-
phocytes also results in the release of large amounts of 
cell-free DNA in the absence of cell death [38, 40, 41]. 
In cancer patients, a fraction of cell-free DNA is tumor-
derived and is termed ctDNA. Cancer patients generally 
have much higher levels of ctDNA than healthy individu-
als, but the levels vary widely, from 0.01% to more than 
90% [12–21, 34]. The variability of ctDNA levels in can-
cer patients likely associates with tumor burden, stage, 
vascularity, cellular turnover, and response to therapy 
[34, 42].
Stability of cell-free DNA is not well understood. Cell-
free circulating DNA appears to be rapidly cleared and 
the spleen, liver, and kidneys are involved in the clear-
ance mechanism [43, 44]. The half-life of cell-free fetal 
DNA was previously estimated to be 16  min [45]. By 
using paired-end massive parallel sequencing (MPS), 
the same group recently studied the kinetics of cell-free 
fetal DNA and found that the clearance of circulating 
fetal DNA occurred in two phases with different kinet-
ics [44]. The initial rapid phase had a mean half-life of 
approximately 1  h, whereas the subsequent slow phase 
had a mean half-life of approximately 13 h [44]. To date, 
very few studies addressed the clearance mechanism of 
ctDNA from plasma. Studies regarding the kinetics and 
clearance of circulating Epstein–Barr virus (EBV) DNA 
may indicate equivalent mechanisms [46–48]. Further-
more, it is also unknown whether other factors such as 
circadian rhythms, inflammation, or particular therapies 
affect ctDNA release and clearance.
Cancer harbors somatic genetic mutations and these 
tumor-specific alterations can be detected in ctDNA. 
Therefore, ctDNA carries genomic and epigenomic alter-
ations concordant to the tumor mutational spectrum, 
such as point mutations, degree of integrity, rearranged 
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genomic sequences, copy number variation (CNV), 
microsatellite instability (MSI), loss of heterozygosity 
(LOH), and DNA methylation [49]. These biological 
characteristics discriminate ctDNA from normal cell-free 
DNA and assure ctDNA as a specific biomarker that pro-
vides personalized information to detect residual disease 
or monitor tumor progression during therapy.
Technologies for ctDNA analysis
Isolation of cell-free DNA for analyses of tumor-spe-
cific alterations is simple to implement from a clinical 
perspective. Circulating DNA is preferably extracted 
from plasma due to lower concentration of background 
wild-type DNA. The amount of cell-free DNA in serum 
can be 2–4 times higher than that in plasma [50], there-
fore, serum could be used for circulating DNA prepa-
ration. However, this is not recommended due to the 
possible contamination of lysed cellular DNA that 
would affect the relative levels of ctDNA. As described 
before, cell-free DNA has limited stability, thus cell-
free DNA preparation should be completed promptly 
after blood draw.
The analysis of ctDNA is challenging and requires 
highly sensitive techniques due to the small fraction of 
tumor-specific DNA masked within background levels 
of wild-type cell-free DNA. Classical methods analyzing 
cell-free DNA include quantitative real-time polymer-
ase chain reaction (PCR)-based, fluorescence-based, and 
spectrophotometric approaches [51–53]. More recently, 
a variety of digital genomic methods have been devel-
oped to improve identification of generic alterations in 
ctDNA. Digital PCR has now emerged as a sensitive tool 
to detect point mutations in ctDNA at low allele fractions 
[54], which comprises droplet-based systems [55, 56], 
microfluidic platforms for parallel PCR [10, 57, 58], and 
an approach called BEAMing (beads, emulsions, amplifi-
cation and magnetics) (Table 1) [34, 59, 60].
Next-generation sequencing technologies are cur-
rently being applied to plasma DNA analysis. These 
high-throughput, low-cost, sequencing technologies 
identify widespread ctDNA alterations across wide 
genomic regions [61–63]. Targeted deep sequenc-
ing approaches have been used to analyze specified 
genomic regions in plasma DNA, including PCR-based 
targeted deep sequencing such as TamSeq [10, 57], 
SafeSeq [64, 65], and Ion-AmpliSeq™ [66, 67] and cap-
ture-based targeted deep sequencing such as CAPP-Seq 
[68] (Table  1). Remarkably, whole genome sequenc-
ing provides novel opportunities for comprehensive 
characterization of the alteration profiles, not just 
limited to predefined or existing mutations in plasma 
DNA [69]. Genome-wide detection of chromosomal 
rearrangements and CNVs can be characterized in 
ctDNA, serving as tumor biomarkers with excel-
lent sensitivity and specificity [70, 71]. Two genome-
wide methods, personalized analysis of rearranged 
ends (PARE) [70, 72] and digital karyotyping [73] can 
be applied to ctDNA detection (Table  1). PARE is a 
method for identifying specific somatic rearrangements 
in tumor tissue and subsequently developing PCR-
based assays to detect these tumor biomarkers in the 
circulation [72, 74]. Digital karyotyping is a genome-
wide technique used to quantify the DNA copy number 
and novel sequences on a genomic scale. It has been 
applied to detect previously uncharacterized chromo-
somal changes and exogenous sequences in human 
tumors [73, 75, 76]. Moreover, recent implementation 
of whole-genome sequencing allows direct application 
to ctDNA analysis, and has provided an unprecedented 
view of somatic chromosomal alterations and CNVs on 
a genome-wide scale [74, 77, 78]. Undoubtedly, with 
continuous improvements in the sensitivity of genomic 
approaches, next generation sequencing techniques 
will play a pivotal role in ctDNA analysis for future 
clinical applications.
Evaluation of cell-free DNA integrity index is a differ-
ent approach to identify ctDNA alterations and consti-
tutes an independent indicator different from any specific 
genomic changes. DNA integrity index is measured as 
the ratio of long to short DNA fragments. Circulating 
cell-free DNA released from apoptotic cells is uniformly 
truncated into 185- to 200-bp fragments [79, 80], whereas 
cell-free DNA released from necrotic tumor cells varies 
in length, which may lead to elevation of DNA with long 
fragments in plasma [30] or serum [81]. A study by Leon 
et  al. [82] suggested that the cell-free DNA concentra-
tion was significantly increased in cancer patients com-
pared with that in healthy individuals. Similar findings 
have also been demonstrated in several cancers such as 
periampullary cancer [80], breast cancer [81], colorectal 
cancer [80], esophageal cancer [83], head and neck can-
cer [84], renal cancer [85], melanoma [86], and prostate 
cancer [87].
Clinical applications of ctDNA
Tumor genotyping: detection of genetic and epigenetic 
alterations
In principle, ctDNA fragments contain genetic defects 
identical to those of tumor tissues, including point muta-
tions, rearrangements, amplifications, MSI, LOH, and 
tumor-associated DNA methylation [88]. To perform 
blood-based tumor genotyping assays by using ctDNA 
will be greatly beneficial for guiding personalized cancer 
treatment (Table 2).
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Detection of tumor‑specific mutations and CNVs
Two separate studies in 1994 first described Kirsten rat 
sarcoma viral oncogene homolog (KRAS) and neuro-
blastoma RAS viral (v-ras) oncogene homolog (NRAS) 
mutations in the blood of pancreatic carcinoma [89] and 
leukemia patients [90]. During the past two decades, 
abundant mutations have been detected in the ctDNA of 
patients with various types of cancer [49]. Next genera-
tion sequencing has been directly applied to ctDNA anal-
ysis. Dawson et  al. [10] used targeted or whole-genome 
sequencing to assess genetic mutations in tumors samples 
from 30 metastatic breast cancer patients, and designed 
personalized assays to quantify ctDNA genetic altera-
tions. They found that ctDNA levels showed a greater 
dynamic range and associated with changes in tumor bur-
den. Leary et  al. [74] published the first whole-genome 
sequencing analysis of ctDNA. They successfully identi-
fied ctDNA in concentrations of less than 1% with a sen-
sitivity >90% and a specificity >99%. Single-nucleotide 
variants (SNVs) and CNV were detected in all advanced-
stage cancer patients, but not in healthy subjects [74]. 
Recently, Chan et al. [77] applied shotgun MPS of plasma 
DNA from cancer patients to scan the cancer genome and 
achieved the genome-wide profiling of CNVs and point 
mutations. Concordant genome-wide SNVs have been 
identified between tumor tissues and pre-surgical cell-
free DNA. Most importantly, the structural alterations in 
plasma DNA entirely disappeared after surgery. Moreo-
ver, the CNV profile detected in ctDNA was derived from 
three primary tumor mixtures in a cancer patient, indi-
cating that ctDNA sequencing is a valuable approach for 
studying tumor heterogeneity [77].
Table 1 Technologies for circulating tumor DNA (ctDNA) detection
PCR polymerase chain reaction, ARMS amplified refractory mutation system, SSCP single-strand conformation polymorphism, Bi-PAP-A amplification bidirectional 
pyrophosphorolysis-activated polymerization allele-specific amplification, BEAMing beads, emulsion, amplification, and magnetics, SafeSeq safe sequencing system, 
TamSeq tagged amplicon deep sequencing, CAPP-Seq cancer personalized profiling by deep sequencing, PARE personalized analysis of rearranged ends, KRAS Kirsten 
rat sarcoma viral oncogene homolog, EGFR epidermal growth factor receptor, PIK3CA phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit alpha, SNV 
single-nucleotide variants, CNVs copy number variations, WES whole-exome sequencing
Principle of detection Method Type of alteration Advantage(s) Limitation(s) Selected reference(s)
PCR-based Nested real-time PCR Known point mutations 
such as KRAS, EGFR, 
and PIK3CA hotspot 
alterations
Ease of use, lowest cost Lower sensitivity, 










Digital PCR BEAMing Known point muta-
tions, genomic rear-
rangements






Microfluidic digital PCR [10]
Targeted deep 
sequencing















Digital karyotyping Genome-wide SNVs,  
CNVs, and rearrange-
ments
Broad application Expensive [73]
PARE [70, 72, 74]
Table 2 Potential application of ctDNA in clinical oncology
Cancer screening Localized cancer Metastatic cancer Refractory cancer
Early diagnosis and 
early intervention
Identifying specific genomic 
alterations to guide therapeutic 
selection, monitoring tumor bur-
den and therapeutic responses, 
detecting minimal residual dis-
ease, assessing risks of dissemina-
tion and recurrence
Early identification of relapse and 
treatment resistance, guidance of 
treatment selection, monitoring 
therapeutic responses
Understanding mechanism of resistance, determin-
ing new treatment
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Detection of MSI and LOH in ctDNA
MSI, such as LOH, is frequently found in tumor tissues. 
Detection of MSI and LOH in ctDNA was first reported 
by Nawroz et  al. [84] in 1996. To date, similar studies 
have been completed in breast, brain, colorectal, ovar-
ian, and prostate cancers [49]. Recently, a study involv-
ing a large cohort of breast cancer patients (n  =  388) 
showed that high LOH frequencies were associated with 
the aggressiveness of breast cancer, and in particular, the 
observed CCND2 loss was a strong indicator of an unfa-
vorable prognosis [91].
Detection of tumor‑associated DNA methylation in ctDNA
DNA methylation plays pivotal roles in gene regulation 
and genome stability. Genes with high levels of 5-methyl-
cytosine in the promoter region are transcriptionally 
silent. This process is often dysregulated in tumor cells. 
Aberrations of DNA methylation in the gene promoter 
region or in the non-coding genomic sequences are asso-
ciated with tumor initiation, dissemination and metas-
tasis establishment, and progression [92]. The status 
of DNA methylation is very stable, even in the circula-
tion; thus it can be assessed to monitor tumor-related 
processes. Aberrant DNA methylation has been first 
detected in the plasma and serum of lung [93], breast 
[94], and liver cancer patients in 1999 [95]. Since then, 
extensive studies have indicated the potential of ctDNA 
methylation as a diagnostic and prognostic marker for 
cancer patients [49, 96–98]. Recently, a study identified 
genome-wide ctDNA methylation in esophageal cancer 
patients, and observed highly concordant methylation 
profiles between ctDNA and corresponding tumor tis-
sues [99]. Differential ctDNA methylation profiles were 
characterized to distinguish esophageal adenocarcinoma, 
precursors, and controls [99]. The study suggested that 
ctDNA can produce excellent methylation profiling on a 
genome-wide scale and serve as a useful tool to develop 
methylation-based biomarkers for clinical application.
Monitoring tumor burden and therapeutic responses
Dynamics of ctDNA has been investigated in various 
solid malignancies for the relationship between ctDNA 
levels, tumor burden, and therapeutic responses [10, 
34, 70, 72, 100, 101]. Protein biomarkers are conven-
tionally used in cancer diagnosis and in the assessment 
of therapeutic responses, such as carcinoembryonic 
antigen (CEA), prostate-specific antigen (PSA), can-
cer antigen (CA) 19-9, and CA-125. Unfortunately, 
the specificity and reliability of these protein biomark-
ers are not satisfactory, and many malignancies even 
do not have any reliable protein biomarker [102, 103]. 
ctDNA carries comprehensive, inherently specific, 
and highly sensitive information, and thus possesses 
distinctive advantage over conventional protein bio-
markers. Studies in melanoma [104, 105], breast [10], 
ovarian [57], and colon cancers [34, 106] have solidified 
the potential applications of ctDNA to monitor tumor 
burden dynamically and precisely during treatment 
process. ctDNA levels increased rapidly with disease 
progression and declined correspondingly after suc-
cessful treatment [10, 34, 57, 104, 105]. Quantitative 
assessment of ctDNA levels could also be an important 
indicator of prognosis (Table 2). Some preliminary data 
supported an association between ctDNA levels and 
prognosis in cancer patients with advanced-stage dis-
ease [10, 107–109].
Treatment resistance is a major problem in the care of 
cancer patients. ctDNA can effectively assess the emer-
gence of mutations associated with treatment resistance 
[110–114]. The molecular alterations of KRAS are caus-
ally associated with the onset of acquired resistance to 
anti-EGFR treatment of colorectal cancers. Detection of 
KRAS variants in ctDNA of patients receiving anti-EGFR 
therapies can identify relapse 10  months before radio-
graphic documentation of disease progression [111]. 
Furthermore, by using whole-exome sequencing, serial 
ctDNA analysis can provide an unbiased and compre-
hensive assessment of genomic alterations during the 
acquisition of treatment resistance [69].
ctDNA analysis can ultimately provide a global picture 
of genetic alterations, including the dynamic changes of 
the mutation profile as well as tumor heterogeneity and 
clonal evolution throughout the course of cancer treat-
ment (Table  2). This global picture can help for design-
ing combination treatments to minimize therapeutic 
resistance.
Monitoring minimal residual disease
ctDNA can be potentially applied to detect minimal 
residual disease after surgery or therapy with curative 
intent [100, 115]. In certain type of cancers, respective 
surgery alone cures a large portion of patients with early-
stage, localized tumor. However, no effective approach 
can discriminate which patients are cured and which 
have residual disease that will result in recurrence. There-
fore, some patients potentially cured by surgery still 
receive adjuvant chemotherapy unnecessarily since lack 
of information. ctDNA is a potential marker for residual 
disease after resection to identify individuals at risk of 
relapse (Table 2). Studies show that assessment of tumor-
specific mutations in plasma DNA following surgical 
resection can identify individuals with residual disease 
[89], and detect disease recurrence [84, 85]. The early 
prediction of recurrence will allow effective treatment 
strategies to be introduced at a time when disease burden 
is still minimal.
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Challenges of ctDNA analysis on the path to clinical 
utility
As a noninvasive “liquid biopsy,” ctDNA is a promising bio-
marker that provides highly specific and complementary 
information in the diagnosis, prognosis, and management of 
cancer treatment. With the rapid advances and the decrease 
in the cost of next-generation sequencing, the technol-
ogy brings a new alternative for unbiased ctDNA explora-
tion. However, clinical routine practice is slow to adopt 
this approach since several challenges remain despite the 
remarkable progress in recent years. Most ctDNA studies 
focused on advanced-stage cancers with relatively high con-
centrations of ctDNA. Detailed experiences with early-stage 
cancer and low concentrations of ctDNA are lacking. High 
levels of normal DNA aggravated during inflammation and 
injury could dilute ctDNA and interfere ctDNA detection. 
Therefore, ctDNA analysis in some clinical settings may 
result from detection of nonprogressing benign lesions. In 
addition, the diverse technologies of ctDNA analysis need to 
be optimized and different platforms need to be standard-
ized, and the appropriate analytic and clinical validity needs 
to be demonstrated, to control the pre-analytic phase and 
obtain robust and reproducible results. Most importantly, 
critical clinical standards need to be established, and well-
designed and sufficiently powered multicenter clinical trials 
involving large cohorts of patients and controls are required 
to validate ctDNA as clinical biomarker.
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